摘要
Purpose To evaluate the prognostic performance of the Child-Turcotte-Pugh (CTP) score and the albumin-bilirubin (ALBI) score in hepatocellular carcinoma (HCC) patients treated using stereotactic ablative radiation therapy (SABR). Methods and Materials This retrospective study evaluated the data of patients with HCC who underwent SABR between December 2007 and June 2015. We collected pretreatment CTP and ALBI scores and analyzed their correlation with survival and liver toxicity. Results This study included 152 HCC patients: 78.3% of CTP class A and 21.7% of CTP class B. The median ALBI score was −2.49 (range, −3.67 to −0.84) with 39.5% of grade 1, 56.6% of grade 2, and 3.9% of grade 3. The CTP classification and ALBI grade were significantly associated with overall survival (P<.001). Albumin-bilirubin grade (1 vs 2) had a trend to stratify CTP class A patients into 2 risk groups of mortality (P=.061). Combined CTP class and ALBI score could predict development of radiation-induced liver disease (2.4% in CTP A-ALBI < −2.76, 15.1% in CTP A-ALBI ≥ −2.76, and 25.8% in CTP B). Conclusion Albumin-bilirubin score is a potential predictor for both survival and liver toxicity. Complementary use of CTP and ALBI score could predict the risk of post-SABR liver toxicity. Further prospective studies are necessary before use of the ALBI score can become part of daily practice.
原文 | 英語 |
---|---|
頁(從 - 到) | 145-152 |
頁數 | 8 |
期刊 | International Journal of Radiation Oncology Biology Physics |
卷 | 99 |
發行號 | 1 |
DOIs | |
出版狀態 | 已發佈 - 9月 1 2017 |
對外發佈 | 是 |
ASJC Scopus subject areas
- 輻射
- 腫瘤科
- 放射學、核子醫學和影像學
- 癌症研究